Heart failure is a massive topic for NEET-PG, but it becomes much easier once you break it down into how we classify it and the "pillars" of management. It's essentially a pump failure—either the pump isn't strong enough (systolic) or it's too stiff to fill up (diastolic).

Let's start with the classifications you'll need to know for the exam, especially the NYHA and ACC/AHA stages.

1. Classification Systems

There are two main ways we classify heart failure in the wards and on exams:

• NYHA (New York Heart Association): Focuses on functional capacity (how the patient feels right now).
  • Class I: No limitation of physical activity.
  • Class II: Slight limitation; comfortable at rest, but ordinary activity causes fatigue/dyspnea.
  • Class III: Marked limitation; comfortable at rest, but less than ordinary activity causes symptoms.
  • Class IV: Symptoms at rest; unable to carry out any physical activity.
• ACC/AHA Stages: Focuses on disease progression (structural changes).
  • Stage A: High risk but no structural disease (e.g., HTN, DM).
  • Stage B: Structural disease present (e.g., low EF) but no symptoms.
  • Stage C: Structural disease with prior or current symptoms.
  • Stage D: Refractory HF requiring specialized interventions.

2. Ejection Fraction (EF) Categories

This is a favorite for MCQ examiners:

• HFrEF (Reduced): EF $\leq$ 40%
• HFmrEF (Mildly Reduced): EF 41–49%
• HFpEF (Preserved): EF $\geq$ 50%

I've got some great lessons that dive deeper into the pathophysiology and these specific stages. Let me pull those up for you.

Now, let's talk about the "Four Pillars" of Guideline-Directed Medical Therapy (GDMT) for HFrEF. This is high-yield because these drugs actually reduce mortality, not just symptoms.

3. The Four Pillars of GDMT

1. ARNI (Sacubitril/Valsartan): Preferred over ACEi/ARBs now. Remember: you need a 36-hour washout period if switching from an ACE inhibitor to avoid angioedema!
2. Beta-Blockers: Only three are proven to reduce mortality: Bisoprolol, Carvedilol, and Metoprolol Succinate (not Tartrate!).
3. MRA (Mineralocorticoid Receptor Antagonists): Spironolactone or Eplerenone. Watch out for hyperkalemia.
4. SGLT2 Inhibitors: Dapagliflozin or Empagliflozin. These are the "new kids on the block" that have revolutionized HF management.

High-Yield Note: Diuretics (like Furosemide) are great for symptoms and "unloading" the patient, but they do NOT reduce mortality.

To help you visualize the management flow, I've put together a clinical algorithm for you.

That flowchart covers the standard approach for HFrEF. For NEET-PG, also keep an eye out for Ivabradine—it's specifically used if the heart rate is still above 70 bpm despite being on a maximum dose of beta-blockers.

Would you like to try some practice questions on this, or should we look at some flashcards to lock in those drug names?